Search NLS News

What if we could silence certain genes to treat a wide range of medical conditions, from genetic conditions to infectious diseases, and even cancer? It may sound like science fiction, but for some rare diseases it’s already a reality through the use of oligonucleotide therapeutics, sometimes referred to as the medicines of the future. But […]

In order to strengthen the company’s liquidity and to ensure the continued development of the company’s pipeline, on July 27, 2022 the Aqilion Board of Directors decided on to carry out an issue with priority for existing owners. The issue was carried out during the third quarter of 2022 as an issue of units, which […]

In the report “The scientific impact of Danish research 1980-2020,” the researchers behind the study state that the scientific impact of Danish research has been on the decline for a number of years. The report was commissioned and funded by the Novo Nordisk Foundation and VILLUM FONDEN and is an update of the report “Fostering […]

Spot-checking is a less time-consuming process than calibration, in part because the calibration process can include as-found data, adjustment (if necessary), and as-left data whereas spot-checking is a verification that the unit under test is still within specification. Field spot-checking is a common way to determine the measurement accuracy of a fixed measurement instrument between […]

Innovation Fund Denmark (Innovationsfonden) has awarded its largest grant for research and development of photothermal therapy to a consortium of four academic groups and FluoGuide. The grant valued at DKK 49.1 million (approx. EUR 6.6 million or SEK 75.6 million) structured through a combination of a cash contribution from Innovation Fund Denmark (50%) and a […]

The company has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies. “We are very happy to receive this license. It is an important milestone for XNK, and we are now well positioned […]

The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing […]

Affibody has announced that data from treatment with izokibep in the open label part (Part A) of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) will be presented. The data from the open label Part A, presented at the American Academy of Dermatology (AAD) Annual Meeting in New Orleans, USA, demonstrated that […]

Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in the USA. The study is led by gastrointestinal cancer expert Dr. Anup Kasi in a three-way clinical collaboration between Kansas University Cancer Center (KUCC), Agenus […]

Cancer Crosslinks 2023 was a day of inspiration, insights, and interactions for professionals from across the cancer field in Norway and beyond. The 15th Cancer Crosslinks was held in Oslo Cancer Cluster Innovation Park on 26 January 2023, gathering the oncology community for a day of engaging talks from renowned international and Norwegian experts. The […]